SRPT FY2025 SEC EDGAR DEF 14A #114 of 168 in industry

Sarepta Therapeutics, Inc. CEO pay ratio

The CEO earned $7.7M in FY2025 against median worker pay of $308,335 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-24
Industry
Chemicals & Pharmaceuticals
Industry rank
#114/168

Data updated August 2026

Subscribe to Sarepta Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
25:1
Below Average (Scale: 0–1000:1)
CEO pay
$7.7M
Median worker
$308,335

Answer first

Sarepta Therapeutics, Inc.'s FY2025 CEO total of $7.7M ranks #709 of 1,423 complete filings; its 25:1 pay ratio ranks #1173. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $308,335. Industry placement uses the FY2025 SIC-28 peer cohort (# 114 of 168, 33rd percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#709
$7.7M of 1,423 FY2025
Ratio rank
#1173
25:1 of 1,423
Industry pct
33rd
below the industry median pay ratio

How Sarepta Therapeutics, Inc. ranks nationally

Sarepta Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$7,708,375 Top 50% higher than 50% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Sarepta Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($7.7M) against pay ratio (25:1) for Sarepta Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both33658.62759449.65485240.58211031.410936822.323.1:128.1:133:138.0:142.9:1CEO total payPay ratio (CEO : median worker)Sarepta Therapeutics, Inc., CEO total pay: 7708375 · Pay ratio (CEO : median worker): 25:1Sarepta Therapeutics, Inc.Siga Technologies Inc, CEO total pay: 3202425 · Pay ratio (CEO : median worker): 25:1Siga Technologies IncArdelyx, Inc., CEO total pay: 7796171 · Pay ratio (CEO : median worker): 25:1Ardelyx, Inc.Biohaven Ltd., CEO total pay: 529257 · Pay ratio (CEO : median worker): 25:1Biohaven Ltd.Vir Biotechnology, Inc., CEO total pay: 7948488 · Pay ratio (CEO : median worker): 24:1Vir Biotechnology, Inc.Mirum Pharmaceuticals, Inc., CEO total pay: 10441224 · Pay ratio (CEO : median worker): 24:1Mirum Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Sarepta Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Sarepta Therapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
25:1
FY2025
vs prior FY
+18:1
from FY2024 7:1
CEO $ YoY
+276%
$7.7M latest
Filings shown
5
FY2021–2025
Sarepta Therapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $1.6M - $271,908 6:1 -
2022 $123.4M +7467% $249,890 494:1 +488:1
2023 $1.5M -99% $308,371 5:1 -489:1
2024 $2.0M +33% $292,690 7:1 +2:1
2025 $7.7M +276% $308,335 25:1 +18:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 873303, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
25:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$7.7M
Companies in Industry
168
vs. Industry Median
Below
#114 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Sarepta Therapeutics, Inc.: MODEST · HEAVY pay ratio

Sarepta Therapeutics, Inc.'s FY2025 ratio 25:1 ranks #114 of 168 Chemicals & Pharmaceuticals filers (33rd percentile). the CEO earned 25× the median employee ($308,335) in FY2025.

Median employee $308,335 (ELITE-MED); MODEST · HEAVY stamps put about 25 median-wage years per CEO year.

CEO Total Pay

$7.7M

FY2025 Summary Compensation, near median

Pay Ratio

25:1

Below typical

Sarepta Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Sarepta Therapeutics, Inc.'s FY2025 ratio 25:1 ranks #114 of 168 Chemicals & Pharmaceuticals filers (33rd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Sarepta Therapeutics, Inc.'s $7.7M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #709 and ratio rank #1173 split - treat 25:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$7.7M
Median Employee Pay
$308,335
Pay Ratio
25:1
Filing Date
2026-04-24

Company Info

Ticker
SRPT
CIK
873303
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 873303, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Sarepta Therapeutics, Inc.'s FY2025 ratio 25:1 ranks #114 of 168 Chemicals & Pharmaceuticals filers (33rd percentile).

Read with Sarepta Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Inspire Medical Systems, Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.7M (Δ $3K heavier vs Sarepta Therapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
YETI Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.7M (Δ $11K lighter vs Sarepta Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Sylvamo Corp · HEAVY

ABS(ceo_total_comp) peer at $7.7M (Δ $23K lighter vs Sarepta Therapeutics, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
United States Lime & Minerals Inc · HEAVY

ABS(ceo_total_comp) peer at $7.7M (Δ $23K lighter vs Sarepta Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Siga Technologies Inc (SIC 28 pole)

Siga Technologies Inc stamps MODEST · MID$ nearest in-SIC by ABS(pay_ratio) to Sarepta Therapeutics, Inc.'s MODEST filing.
National dual ranks · #709/#1173

Sarepta Therapeutics, Inc.'s FY2025 package sits #709 by CEO dollars and #1173 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Sarepta Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Sarepta Therapeutics, Inc. (CIK 873303), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.